Johns Hopkins HIV Guide
Tenofovir alafenamide (TAF)
INDICATIONS
FDA
FDA
- Treatment of HIV-1 infection as part of a single-tablet regimen (STR), Genvoya or Odefsey, or NRTI combination tablet Descovy, for adults and pediatric patients 12 years of age and older who are treatment-naive or to replace the current antiretroviral regimen in those who are virologically suppressed.
- Treatment of chronic HBV infection in adults and children ≥ 12 years with compensated liver disease.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: March 15, 2025
Citation
Auwaerter, Paul G, and Janessa M Smith. "Tenofovir Alafenamide (TAF)." Johns Hopkins HIV Guide, The Johns Hopkins University, 2025. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545252/all/Tenofovir_AF.
Auwaerter PG, Smith JM. Tenofovir alafenamide (TAF). Johns Hopkins HIV Guide. The Johns Hopkins University; 2025. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545252/all/Tenofovir_AF. Accessed September 27, 2025.
Auwaerter, P. G., & Smith, J. M. (2025). Tenofovir alafenamide (TAF). In Johns Hopkins HIV Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545252/all/Tenofovir_AF
Auwaerter PG, Smith JM. Tenofovir Alafenamide (TAF) [Internet]. In: Johns Hopkins HIV Guide. The Johns Hopkins University; 2025. [cited 2025 September 27]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545252/all/Tenofovir_AF.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Tenofovir alafenamide (TAF)
ID - 545252
A1 - Auwaerter,Paul,M.D.
AU - Smith,Janessa,PharmD, BCPS
Y1 - 2025/03/15/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545252/all/Tenofovir_AF
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
